Cyber Monday Steal Vgo 30 - Insulin Delivery Device 30 Units Basal Rate Over 24 Hours, 36 Bolus Units, 30 Subcutaneous Injection Devices - 8560-9400-02 50% Off - Today Only [4TI38VQY]

VGO 30 Insulin Delivery Device - Simplify Your Insulin Management

Introducing the VGO 30, the ultimate insulin delivery device designed to simplify your insulin management. This innovative device offers a 30-unit basal rate over 24 hours, providing consistent and reliable insulin delivery. With its user-friendly design and versatile features, the VGO 30 is perfect for individuals with diabetes seeking a convenient and efficient way to manage their insulin therapy.

• One insulin type required
• Safe for use with U-100 fast-acting insulin

Key Features and Specifications of VGO 30

The VGO 30 is a comprehensive insulin delivery solution that includes 36 bolus units and 30 subcutaneous injection devices. This device is specifically designed to work with U-100 fast-acting insulin, ensuring optimal absorption and effectiveness. With a total of 66 units of insulin available, the VGO 30 offers flexibility in dosing to meet your individual needs.

• 30-day supply in 3 basal rate options
• 36 bolus units for customizable dosing

The VGO 30 is also equipped with 30 subcutaneous injection devices, providing a convenient and hassle-free insulin delivery experience.

Practical Uses and Benefits of VGO 30

The VGO 30 is an invaluable tool for individuals managing their diabetes, offering numerous benefits in daily life. With its 30-day supply and three basal rate options, this device allows for personalized insulin management, ensuring consistent blood sugar control. The VGO 30 is a compact and discreet solution, making it ideal for on-the-go use. Whether you're at work, school, or traveling, the VGO 30 ensures that your insulin therapy is always within reach.

• Convenient and discreet insulin delivery
• Customizable dosing for personalized insulin management

The VGO 30 is designed for individuals who value simplicity, convenience, and efficiency in their insulin therapy.